Studies cannabis use and quality of life in people with multiple myeloma
Observes how cannabis use may affect quality of life in adults with myeloma receiving chemotherapy.
Plain-language title generated from the registry record
Registry title: A Multicenter Prospective Observational Cohort Study Evaluating the Impact of Cancer-Directed Treatment and Medication Use, Including Cannabis Use, in Multiple Myeloma Patients
Key facts
- Where
- Duarte, Goodyear, Huntington Beach, Irvine, Long Beach, Newnan, Newport Beach, South Pasadena, Upland, West Covina, and Zion, United StatesSee the 11 sites
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with newly diagnosed multiple myeloma who have had little or no first treatment. It studies how cannabis use affects quality of life. Some health care workers can also join a survey.
- Age
- 18 years or older
- Sex
- All sexes can join.
- Disease stage
- Newly diagnosed multiple myeloma, confirmed by tissue examination. ECOG of 3 or lower.
- Earlier treatment
- Patients may have started first line therapy and had up to four cycles. They must not have completed five cycles of first line therapy or had any second line therapy. They must not have had an autologous stem cell transplant.
Main reasons for not taking part
- Another active cancer
- Completed five cycles of first line therapy or had second line therapy
- Had an autologous stem cell transplant
- Cannot take part in the study assessments
- Cannot read and understand English
Read by machine on 9 November 2026.
Where in United States
- City of Hope Medical CenterDuarte, United StatesTaking people
- CTCA at Western Regional Medical CenterGoodyear, United StatesNot yet recruiting
- City of Hope SeacliffHuntington Beach, United StatesNot yet recruiting
- City of Hope at Irvine LennarIrvine, United StatesTaking people
- City of Hope at Long Beach ElmLong Beach, United StatesNot yet recruiting
- City of Hope Atlanta Cancer CenterNewnan, United StatesNot yet recruiting
- City of Hope at Newport Beach Fashion IslandNewport Beach, United StatesNot yet recruiting
- City of Hope South PasadenaSouth Pasadena, United StatesNot yet recruiting
- City of Hope UplandUpland, United StatesNot yet recruiting
- City of Hope West CovinaWest Covina, United StatesNot yet recruiting
- City of Hope at ChicagoZion, United StatesNot yet recruiting
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- City of Hope Medical Center
- Trial code
- NCT07225738
- Record updated
- 20 February 2026
- Original description
This study assesses the impact of cannabis (also commonly called marijuana, weed, or THC) use on quality of life among patients with multiple myeloma who are receiving chemotherapy. It also evaluates the potential benefits and harms of cannabis use.Read full original descriptionShow less
A Multicenter Prospective Observational Cohort Study Evaluating the Impact of Cancer-Directed Treatment and Medication Use, Including Cannabis Use, in Multiple Myeloma Patients
This study assesses the impact of cannabis (also commonly called marijuana, weed, or THC) use on quality of life among patients with multiple myeloma who are receiving chemotherapy. It also evaluates the potential benefits and harms of cannabis use.
Inclusion: * Documented informed consent of the participant; Age: ≥ 18 years; ECOG ≤ 3; Ability to read and understand English; Patient must be newly diagnosed with a histologically confirmed multiple myeloma; Patients may have started first line therapies and received up to four cycles; HCP SURVEY: Documented informed consent of the participant; HCP SURVEY: Age: ≥ 18 years; HCP SURVEY: Licensed physician, physician assistant, nurse practitioner, or registered nurse; HCP SURVEY: Currently practicing in oncology or providing direct care to oncology patients; HCP SURVEY: Able to read and understand English; HCP SURVEY: Affiliation with City of Hope.
Exclusion: * Patients may not have completed five cycles of first line therapy or undergone any second line therapy; Other active malignancy; Patients may not have undergone autologous hematopoietic stem cell transplantation; Unable to comply with the study assessments; HCP SURVEY: Reports directly to study PI (Dr. Richard Lee); HCP SURVEY: Member of the study team or involved in survey design or analysis; HCP SURVEY: Individuals with a real or perceived conflict of interest that could bias survey responses.